AI Agent Flags Drug Safety Risks Before First Human Trial Dose

A developer has built TrialSleuth AI, an agent that reviews a new drug's composition, dosing, eligible patients, trial design, interacting medicines and existing lab results before its first human dose. The tool produces an overall risk level and risks by body system, each tied to supporting evidence. It also suggests changes such as lower starting doses, patient exclusions, banned interacting medicines, and tests to run first. The system stores past drug results in a memory layer built on Hindsight, an open-source agent memory system, so it can compare new drugs against prior cases. Its developer stresses that the tool never declares a drug safe, but aims to surface known risks early for expert review.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in